Pneumologia
Impacto da doença pulmonar obstrutiva crônica e fatores de risco a ela atribuídos em 204 países e territórios, 1990-2019: resultados do Global Burden of Disease Study 2019.
4 Ago, 2022 | 14:28hComunicado de imprensa: Chronic lung disease remains major public health problem – BMJ Newsroom
Comentário no Twitter
New research finds that despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index https://t.co/uUkQYCSmBY
— The BMJ (@bmj_latest) July 30, 2022
Revisão atualizada da estenose subglótica: etiologia, avaliação e tratamento.
4 Ago, 2022 | 14:12hAn Updated Review of Subglottic Stenosis: Etiology, Evaluation, and Management – Current Pulmonology Reports (se o acesso a este link for pago, tente este)
Revisão sistemática | Testes rápidos de antígeno para diagnóstico de infecção por SARS-CoV-2.
1 Ago, 2022 | 15:23hRapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection – Cochrane Library
Resumo: How accurate are rapid antigen tests for diagnosing COVID-19? – Cochrane Library
M-A | Ocorrência de câncer de pulmão após episódio de tuberculose.
1 Ago, 2022 | 15:16h
Revisão | Exames de imagem na síndrome da angústia respiratória aguda: passado, presente e futuro.
18 Jul, 2022 | 13:38hImaging the acute respiratory distress syndrome: past, present and future – Intensive Care Medicine
Comentário no Twitter
Imaging #ARDS: past, present & future
➡️ physiopathology
➡️ management: PEEP/recruitment; inflation (& hyperinfation)
➡️ effects of proning on ventilation/perfusion
➡️ lung infammation
➡️ #COVID19
➡️ identifying complications
➡️ prognostication
& more!
📎 https://t.co/tEp50muK8J pic.twitter.com/GlME1vTePh— Intensive Care Medicine (@yourICM) July 14, 2022
Estudo randomizado | Tixagevimabe-cilgavimabe para tratamento de pacientes internados com COVID-19.
18 Jul, 2022 | 13:36hComentário: The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients – News Medical
Conteúdos relacionados:
Comentário no Twitter
In pts hospitalised w/ COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve time to sustained recovery but was safe and mortality was lower vs placebo
From the ACTIV-3–TICO Study Group https://t.co/zaaXBQYl5t pic.twitter.com/xe0tmbFrZ9
— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022
Revisão | Infecções fúngicas respiratórias invasivas em pacientes críticos com COVID-19.
18 Jul, 2022 | 13:33hInvasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients – Journal of Fungi
Guia para tratamento de pacientes com câncer de pulmão de não pequenas células estágio 1: decisão entre lobectomia, segmentectomia, radiocirurgia estereotáxica corpórea (stereotactic body radioation therapy – SBRT) e ablação.
18 Jul, 2022 | 13:31hA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation – Journal of Thoracic Disease
Parte 1 – A guide to decision-making
Parte 2 – Systematic review of evidence regarding resection extent in generally healthy patients
Parte 3 – Systematic review of evidence regarding surgery in compromised patients or specific tumors
Parte 4 – Systematic review of evidence involving SBRT and ablation
M-A (maioria de estudos observacionais) | Trombólise guiada por cateter vs. anticoagulação sistêmica isolada para embolia pulmonar submaciça.
18 Jul, 2022 | 13:20h
Revisão | Strongyloides stercoralis.
18 Jul, 2022 | 13:11hStrongyloides stercoralis – Lung (se o acesso a este link for pago, tente este)